Roche’s Columvi passes Phase 3 lymphoma test as competition with AbbVie, Genmab continues
Roche’s Columvi is on the path to a full approval and potentially a label expansion in an earlier lymphoma setting after hitting the primary endpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
